Table 6. Comparison of studies available in current literature.
| Study, year | Souhami et al [17], 1993 | Toita et al [21], 2005 | Pötter et al [33], 2006 | Atahan et al [16], 2007 | Parker et al [18], 2009 | Kato et al [20], 2010 | Al Asiri et al [22], 2013 | Giavedoni, 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| QT/RT concurrency (n) | 50 | 40 | 48 | 89/183 | 92 | 120 | 74 | 43 | |
| Country | Canada | Japan | Austria | Turkey | UK | South-east Asia | Saudi Arabia | Argentina | |
| FIGO stage (I, II, III, IV) (%) | 0, 40, 54, 6 | 2, 33, 65, 0 | 4, 50, 42, 4 | 10, 64, 26, 0 | 8, 63, 26, 3 | 0, 0, 50, 50 | 0, 66, 26, 8 | 28, 49, 23, 0 | |
| Radiant treatment used | Technique | Conventional (2D) | Conventional (2D) with 18 MV | CT based 3D conformal | Conventional (2D) | Conventional (2D) | Conventional (2D) ALE/60 CO | CT based 3D conformal | CT based 3D conformal |
| EBRT (DT) Gy | 46 | 50 | 50 | 50 | 45 | 50 | 45–50.4 | 50 | |
| Fields | four-field box | APPA | four-field box | four-field box o APPA | four-field box | four-field box or APPA | APPA | four- field box | |
| Boost | — | yes | — | — | — | yes | — | yes | |
| Dose Boost (Gy) | — | 6–10 | — | — | — | 10-15 | — | 5.4 | |
| Brachytherapy (BT) | HDR-BT 30 Gy (3 × 10 Gy) | HDR-BT 18 Gy (3 × 6 Gy) | MRI- based 3D HDR-BT (5–6 o 7 ×7 Gy) |
HDR-BT 28 Gy (4 × 7 Gy) | HDR-BT 24 Gy (4 × 6 Gy) | LDR-BT or HDR-BT | HDR-BT 28 Gy (4–6 ×7 Gy) | HDR-BT/ TAC- based 3D 24 Gy (4 × 6 Gy) | |
| Follow-up | Survival rate Early global (months) | 65% to 44 | 79% to 36 | 61% to 36 | — | 72% to 24 | 79.6% to 24 | — | 82.9% to 24 |
| Rate of SG to 5 years (%) | — | — | — | 55 | 55 | — | 64.5 | — | |
| Median of Follow-up (months) | 27 | 37 | 33 | 45 | 26 | 27.3 | 60 | 32 | |
| Rate of Local relapse (%) | 7 (16%) | 3 (7%) | 10 (21%) | 48 (26%) | — | 14 (12%) | 8 (11%) | 3 (9%) | |
| Toxicity | Classification of toxicity (acute// chronic) | RTOG// Pilepich% | NCI-CTC version 2.0// RTOG/EORTG | NCI// LENT SOMA score | RTOG/ EORTG// RTOG/ EORTG | // NCI-CTC version 3.0 | NCI-CTC version 3.0// RTOG/ EORTG | NCI-CTC version 2.0// RTOG/ EORTG | NCI-CTC version 3.0 y RTOG/ EORTG// RTOG/ EORTG |
| Late toxicity G3 or G4 (%) | 13/50 (26) | 1/40 (2.5) | 2 (4) | 8/183 (8) | 4/92 (4) | 3/120 (4) | 3 (4) | 14/43 (32.5) | |
| Areas evaluated - Chronic toxicity | bladder, bowel | bladder, bowel | vagina, bladder, bowel | bladder, bowel | vagina, bladder, bowel, neuromusc/ ext | bladder, bowel | urinary tract, bowel, neuropathy, hearing loss | vagina, bladder, bowel, neuromusc/ ext | |
QT/RT: chemoradioconcurrence, FIGO: International Federation of Gynecologists and Obstetrics, CT: computed tomography, 3D: three dimensional, ALE: linear accelerator, 60CO: cobalt 60, Gy: grey, APPA: anterior-posterior, HDR- BT: high rate brachytherapy, LDR- BT: low rate brachytherapy, MRI: magnetic resonance imaging, SG: global survival, RTOG: Radiation Therapy Oncology Group, NCI-CTC: Common Toxicity Criteria of the National Cancer Institute, RTOG/EORTG: European Organization for Research and Treatment of Cancer, LENT SOMA: Late Effects Normal Tissue Task Force- Subjective, Objective, Management, Analytic scales, Neuromuscular/ext: neuromuscular/extremities % Pilepich, M. International Journal of Radiation Oncology, Biology, Physics. 1987; 13 (3):351–357, EBRT: External Beam Radiation Therapy, DT: Total dose, TAC/TC/CT: computed axial tomography